JHVEPhoto / Shutterstock.com
Israel-based Teva has predicted 2019 will be a tough year, with lower revenue and profit, as the company faces generic competition for two of its top-selling drugs.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Teva, generics, revenues, full-year results, generic competition, Copaxone, ProAir, generic sales, Kåre Schultz, research and development, R&D